Isao Hidaka

Isao Hidaka

Auto-generated profile, based on publicly available information

Isao Hidaka

Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
MIMichiko Itoh
Michiko Itoh
TSTakayoshi Suganami
Takayoshi Suganami
HKHideaki Kato
Hideaki Kato
SKSayaka Kanai
Sayaka Kanai
ISIbuki Shirakawa
Ibuki Shirakawa
YOYoshihiro Ogawa
Yoshihiro Ogawa
Although recent evidence has pointed to the role of organ- and pathogenesis-specific macrophage subsets, it is still unclear which subsets are critically involved in the pathogenesis of nonalcoholic steatohepatitis (NASH). Using melanocortin-4 receptor–deficient (MC4R-KO) mice fed Western diet (WD), which exhibit liver phenotypes similar to those of human NASH, we found a histological structure, termed hepatic crown-like structure (hCLS), in which CD11c + macrophages surround dead/dying hepatocytes, a prominent feature of NASH. Here, we demonstrate that hCLS-constituting macrophages could be a novel macrophage subset that drives hepatocyte death-triggered liver fibrosis. In an “inducible NASH model,” hepatocyte death induces hCLS formation and liver fibrosis sequentially in the short term. In combination with the long-term WD feeding model, we also showed that resident macrophages are a major cellular source of CD11c + macrophages constituting hCLS, which exhibited gene expression profiles distinct from CD11c – macrophages scattered in the liver. Moreover, depletion of CD11c + macrophages abolished hCLS formation and fibrogenesis in NASH. Our clinical data suggest the role of CD11c + macrophages in the disease progression from simple steatosis to NASH. This study sheds light on the role of resident macrophages, in addition to recruited macrophages, in the pathogenesis of NASH.

25 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ISIssei Saeki
Issei Saeki
Takahiro YamasakiTakahiro Yamasaki
Takahiro Yamasaki
SYSatoyoshi Yamashita
Satoyoshi Yamashita
THTadasuke Hanazono
Tadasuke Hanazono
YUYohei Urata
Yohei Urata
ISIsao Sakaida
Isao Sakaida
There are limited reports regarding early predictors of objective response (OR) in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study including 70 patients aimed to investigate the efficacy of hepatic biochemical markers. Changes in tumor marker (alpha-fetoprotein (AFP)/des-gamma-carboxy prothrombin (DCP)) levels and albumin–bilirubin (ALBI) score between the baseline value and that estimated one month after treatment were evaluated. We identified several predictors of OR, including changes in tumor marker levels. The OR rate calculated using modified Response Evaluation Criteria in Solid Tumor (mRECIST) was 41.4%. Response was defined as a reduction in AFP and DCP levels of ≥40% from baseline. OR was significantly associated with AFP response, but not with DCP. Predictors of OR were evaluated in two groups (high-AFP group: baseline AFP ≥ 10 ng/mL; low-AFP group: remaining patients). A multivariate analysis identified AFP response (odds ratio, 51.389; p = 0.001) and ALBI score (odds ratio, 6.866; p = 0.039) as independent predictors of OR in the high-AFP and low-AFP groups, respectively. Changes in the ALBI score indicated deterioration in both responders and non-responders, with a significant difference in non-responders (p = 0.003). AFP response, baseline ALBI score, and change in the ALBI score were early predictors of OR in patients with HCC undergoing lenvatinib treatment.

5 August 2020 in Applied Sciences
Verified
Journal Article
Open access
PDF file
YKYurika Kotoh
Yurika Kotoh
ISIssei Saeki
Issei Saeki
Takahiro YamasakiTakahiro Yamasaki
Takahiro Yamasaki
RSRyo Sasaki
Ryo Sasaki
NTNorikazu Tanabe
Norikazu Tanabe
ISIsao Sakaida
Isao Sakaida
Previous studies have reported prognostic factors for hepatocellular carcinoma (HCC) patients receiving lenvatinib; however, no studies have evaluated the effects of both handgrip strength and skeletal muscle mass on the clinical outcomes. Therefore, this retrospective study investigated the individual effect of handgrip strength, skeletal muscle mass, and sarcopenia on clinical outcomes of 53 HCC patients treated with lenvatinib. Before receiving lenvatinib, handgrip strength and skeletal muscle index (SMI) were measured. Low handgrip strength and muscle depletion were defined as <26 and <18 kg and SMI <42 and SMI <38 cm2/m2 in men and women, respectively. Sarcopenia was defined as having low handgrip strength and muscle depletion. Multivariate analysis identified modified albumin–bilirubin grade 1–2a (p = 0.010), Barcelona Clinic Liver Cancer stage A–B (p = 0.011), and absence of low handgrip strength (p = 0.015) as favorable prognostic factors for survival. Furthermore, sarcopenia was an independent significant prognostic factor for survival. Time to treatment failure was associated with handgrip strength and sarcopenia. Our findings suggest that handgrip strength may be a useful marker of clinical outcomes in HCC patients treated with lenvatinib.

5 March 2021 in JGH Open
Verified
Journal Article
Open access
PDF file
THTakuro Hisanaga
Takuro Hisanaga
IHIsao Hidaka
Isao Hidaka
ISIsao Sakaida
Isao Sakaida
NNNobuaki Nakayama
Nobuaki Nakayama
AIAkio Ido
Akio Ido
IJIntractable Hepato‐Biliary Disease Study Group of Japan
Intractable Hepato‐Biliary Disease Study Group of Japan
Background and Aim: In Japan, corticosteroids have been commonly used as a part of multidisciplinary therapy for patients with acute liver failure and late‐onset hepatic failure. However, there is controversy regarding the development of infections and other complications. In this study, the influence of corticosteroids on patient outcomes after liver transplantation was investigated.Methods: This study included 167 patients with acute liver failure and late‐onset hepatic failure who underwent liver transplantation between 2010 and 2015. The effects of pretransplant corticosteroid therapy on patient outcomes were evaluated using a database constructed by the subcommittee for fulminant hepatitis in the Intractable Hepato‐Biliary Diseases Study Group of Japan.Results: The subacute type and the median total bilirubin levels were higher in those receiving corticosteroids than in those not receiving corticosteroids. Although infections tended to be higher in patients receiving corticosteroids, pretransplant corticosteroid administration did not affect the survival rates. The duration from corticosteroid initiation to liver transplantation was longer in patients who developed infections. The survival rates, however, did not differ between patients with and without infections.Conclusions: Corticosteroids were administered to patients with poor prognoses. Otherwise, the overall outcome in those administered corticosteroids was not significantly different from that in those administered without corticosteroids. Although infectious complications tended to occur, they were generally controllable and nonfatal. Pretransplant corticosteroid therapy may be permissible, with regarding for infections and performed within the minimum duration.

1 February 2021 in Kanzo
Verified
Journal Article
Open access
PDF file
Masaru EnomotoMasaru Enomoto
Masaru Enomoto
IHIsao Hidaka
Isao Hidaka
TITaisuke Inoue
Taisuke Inoue
HIHiroshi Isoda
Hiroshi Isoda
TITatsuya Ide
Tatsuya Ide
MKMasaaki Korenaga
Masaaki Korenaga
In Japan, each prefecture in collaboration with regional core centers is required to train hepatitis medical care coordinators (HMCCs). In this study, we surveyed the present status of HMCCs in 17 of the 71 regional core centers. The findings indicated that the number of HMCCs varied from 8 to 77 per regional core center. The proportion of HMCCs who actively contributed to hepatitis patient care also varied from 7.9% to 100%. Among the HMCCs, 50% were nurses, 11% clinical laboratory technicians, 8.0% pharmacists, 8.0% registered dietitians, and 3.5% doctors. The results of the survey show that, in each regional core center, there is a substantial variety in the present status of HMCCs.

20 February 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Takahiro YamasakiTakahiro Yamasaki
Takahiro Yamasaki
ISIssei Saeki
Issei Saeki
YKYurika Kotoh
Yurika Kotoh
RSRyo Sasaki
Ryo Sasaki
NTNorikazu Tanabe
Norikazu Tanabe
ISIsao Sakaida
Isao Sakaida
Recent success of systemic therapeutic agents, including combination immunotherapy, could promote a change in the treatment strategy in patients with advanced hepatocellular carcinoma (HCC). Although hepatic arterial infusion chemotherapy (HAIC) is a treatment option for advanced HCC in Japan, it is not recommended by other guidelines. We discuss the clinical benefits of HAIC compared to sorafenib. The clinical benefits of HAIC are as follows: (1) even a patient with Child–Pugh B HCC (7 or 8 points) is a candidate for HAIC (2) Child–Pugh scores barely decline with the use of HAIC compared with sorafenib (3) HAIC is highly effective in patients with vascular invasion compared with sorafenib; and (4) survival in patients receiving HAIC may not be associated with skeletal muscle volume. In contrast, the disadvantages are problems related with the reservoir system. HAIC has clinical benefits in a subpopulation of patients without extrahepatic metastasis with Child–Pugh A HCC and vascular invasion (especially primary branch invasion or main portal vein invasion) or with Child–Pugh B HCC.